News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,247 Results
Type
Article (2445)
Company Profile (39)
Press Release (35763)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (14124)
Career Advice (77)
Deals (2078)
Drug Delivery (9)
Drug Development (4100)
Employer Resources (10)
FDA (432)
Job Trends (763)
News (20140)
Policy (1052)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (144)
Allergies (6)
Alliances (3474)
ALS (4)
Alzheimer's disease (46)
Antibody-drug conjugate (ADC) (17)
Approvals (434)
Artificial intelligence (11)
Autoimmune disease (4)
Automation (1)
Bankruptcy (12)
Best Places to Work (475)
BIOSECURE Act (2)
Biosimilars (14)
Biotechnology (29)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (20)
Cancer (145)
Cardiovascular disease (6)
Career advice (64)
Career pathing (1)
CAR-T (16)
Cell therapy (45)
Cervical cancer (2)
Clinical research (3180)
Collaboration (94)
Compensation (49)
COVID-19 (180)
CRISPR (7)
C-suite (30)
Cystic fibrosis (2)
Data (114)
Denatured (3)
Depression (3)
Diabetes (10)
Diagnostics (465)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (15)
Drug pricing (8)
Duchenne muscular dystrophy (12)
Earnings (4242)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6040)
Executive appointments (96)
FDA (480)
Featured Employer (3)
Funding (80)
Gene editing (14)
Gene therapy (19)
GLP-1 (60)
Government (149)
Healthcare (705)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (17)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (989)
IRA (7)
Job creations (290)
Job search strategy (62)
Kidney cancer (4)
Labor market (4)
Layoffs (38)
Leadership (1)
Legal (212)
Liver cancer (5)
Lung cancer (15)
Lymphoma (4)
Management (4)
Manufacturing (19)
MASH (4)
Medical device (307)
Medtech (307)
Mergers & acquisitions (1159)
Metabolic disorders (34)
Multiple sclerosis (8)
Neurodegenerative disease (9)
Neuropsychiatric disorders (3)
Neuroscience (92)
NextGen: Class of 2025 (352)
Non-profit (153)
Northern California (367)
Now hiring (4)
Obesity (16)
Opinion (15)
Ovarian cancer (10)
Pain (9)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (2)
Patents (24)
Patient recruitment (5)
Peanut (1)
People (5663)
Pharmaceutical (5)
Phase I (1374)
Phase II (1595)
Phase III (846)
Pipeline (77)
Policy (12)
Postmarket research (30)
Preclinical (594)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (22)
Real estate (420)
Recruiting (5)
Regulatory (806)
Reports (6)
Research institute (142)
Resumes & cover letters (9)
Schizophrenia (10)
Series A (26)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Southern California (361)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (489)
Stomach cancer (1)
Supply chain (4)
The Weekly (1)
United States (1761)
Vaccines (28)
Venture capitalists (8)
Weight loss (12)
Women's health (1)
Worklife (1)
Date
Today (2)
Last 7 days (54)
Last 30 days (217)
Last 365 days (2535)
2025 (796)
2024 (2613)
2023 (2859)
2022 (3754)
2021 (4048)
2020 (3471)
2019 (2061)
2018 (1556)
2017 (1795)
2016 (1624)
2015 (1834)
2014 (1370)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (43)
Alabama (1)
Arizona (15)
Asia (1868)
Australia (298)
California (848)
Canada (134)
China (40)
Colorado (20)
Connecticut (10)
Delaware (4)
Europe (3824)
Florida (44)
Georgia (5)
Idaho (3)
Illinois (15)
India (1)
Indiana (33)
Japan (7)
Kansas (12)
Maryland (25)
Massachusetts (305)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (3)
New Hampshire (2)
New Jersey (70)
New York (49)
North Carolina (90)
Northern California (367)
Ohio (26)
Oklahoma (2)
Oregon (5)
Pennsylvania (51)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (361)
Tennessee (2)
Texas (72)
Utah (2)
Virginia (6)
Washington D.C. (1)
Washington State (53)
Wisconsin (6)
38,247 Results for "coherus biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
March 11, 2025
·
23 min read
Press Releases
Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio
April 14, 2025
·
9 min read
Press Releases
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
April 14, 2025
·
8 min read
Press Releases
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
April 2, 2025
·
10 min read
Deals
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction– Transaction aligns with Coherus’ strategic focus on oncology –
Coherus BioSciences, Inc today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash consideration of $40 million.
June 27, 2024
·
4 min read
Business
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Coherus BioSciences, Inc., reported financial results for the quarter ended March 31, 2024 and recent business highlights.
May 9, 2024
·
14 min read
Press Releases
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
February 25, 2025
·
1 min read
Press Releases
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 7, 2024
·
20 min read
Press Releases
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
March 4, 2025
·
2 min read
Business
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for its fiscal fourth quarter and full year ended December 31, 2023 and recent business highlights.
March 13, 2024
·
19 min read
1 of 3,825
Next
